Primary Mediastinal Large B-Cell Lymphoma: A Clinicopathologic Study of 43 Patients From the Nebraska Lymphoma Study Group PURPOSE: Rituximab was recently approved for use in relapsed, low-grade ...

The U.S. Food and Drug Administration (FDA) has approved Epkinly (epcoritamab-bysp) plus Revlimid (lenalidomide) and Rituxan ...

Pediatric patients receiving a combination of rituximab and cyclophosphamide therapy for rheumatic disease showed clinical improvement with a low risk for adverse effects. While current clinical ...

A trial evaluated whether rituximab can attain remission in adults with frequently relapsing nephrotic syndrome (FRNS) or steroid dependent nephrotic syndrome (SDNS).

FDA approved tafasitamab with lenalidomide and rituximab for relapsed or refractory follicular lymphoma, based on clinical trial results. Troy Anderson's experience with Monjuvi showed significant ...